Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | TPMT | P51580 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15660186 | 0.91 | PTPN2 (0.38) | PTPN2PTPN1TPMTCA1CA2 | |
| SCHEMBL300884 | 0.91 | CA12 (0.42) | CA1CA2ALDH1A1HPGDCA12 | |
| SCHEMBL13455758 | 0.85 | SMN1; SMN2 (0.44) | CA1CA2ALDH1A1HPGDCA12 | |
| SCHEMBL27717830 | 0.84 | CA1 (0.55) | TPMTCA1CA2ALDH1A1HPGD | |
| SCHEMBL5648489 | 0.84 | CA12 (0.47) | CA1CA2ALDH1A1HPGDCA12 | |
| SCHEMBL12216547 | 0.82 | LMNA (0.44) | CA1ALDH1A1HPGDCA12CA9 | |
| SCHEMBL1696262 | 0.82 | KDM4E (0.42) | CA1CA2ALDH1A1HPGDKMT2A | |
| SCHEMBL10070313 | 0.82 | ALDH1A1 (0.37) | CA1ALDH1A1HPGDCA12CA9 | |
| SCHEMBL22076666 | 0.82 | MGLL (0.33) | CA1CA12CA9KMT2AMGLL | |
| SCHEMBL1800956 | 0.82 | PTPRF (0.44) | PTPN2PTPN1CA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115281-A1 | TRITERPENE SAPONIN ANALOGUES | ADJUVANCE TECH INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4724457-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Rayzebio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12569554-B2 | Triterpene saponin analogues | ADJUVANCE TECHNOLOGIES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| WO-2024254339-A9 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025199636-A1 | TARGETED RADIOLIGAND COMPOUNDS AND USES THEREOF | MCMASTER UNIVERSITY (CA) | 2025-10-02 | — | — | WO | disclosed |
| US-20250257148-A1 | ATP-Dependent Agonists of Immune Cells Function as Anticancer Agents | CROSSLINK THERAPEUTICS INC (US) | 2025-08-14 | — | — | US | disclosed |
| EP-4594337-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING EPHRIN TYPE-A RECEPTOR 2 AND USES THEREOF | Rayzebio, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025054553-A1 | ATP-DEPENDENT AGONISTS OF IMMUNE CELLS FUNCTION AS ANTICANCER AGENTS | CROSSLINK THERAPEUTICS INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2024254339-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-20240327443-A1 | TRITERPENE SAPONIN ANALOGUES | ADJUVANCE TECHNOLOGIES, INC. (US) | 2024-10-03 | — | — | US | disclosed |
| US-20050214307-A1 | Antibody conjugates for treatment of neoplastic disease | RESEARCH DEVELOPMENT FOUNDATION | 2005-09-29 | — | — | US | disclosed |
| US-20050100528-A1 | Novel antibody delivery system for biological response modifiers | ROSENBLUM MICHAEL G (US) | 2005-05-12 | — | — | US | disclosed |
| US-6750329-B1 | FOR TREATING PROLIFERATIVE CELL DISEASES, COMPRISING ADMINISTRATION OF A CYTOTOXICALLY EFFECTIVE DOSE OF A CONJUGATE, COMPRISING A ZME-018 ANTIBODY TARGETING A CELL SURFACE ASSOCIATED ANTIGEN AND A BIOLOGICAL RESPONSE MODIFIER | RESEARCH DEVELOPMENT FOUNDATION | 2004-06-15 | — | — | US | disclosed |
| EP-0920623-A4 | BORON NEUTRON CAPTURE THERAPY USING PRE-TARGETING METHODS | IMMUNOMEDICS INC (US) | 2000-03-29 | — | — | EP | disclosed |
| EP-0920623-A1 | BORON NEUTRON CAPTURE THERAPY USING PRE-TARGETING METHODS | Immunomedics, Inc. (US) | 1999-06-09 | — | — | EP | disclosed |
| US-5846741-A | Boron neutron capture therapy using pre-targeting methods | IMMUNOMEDICS, INC. (US) | 1998-12-08 | — | — | US | disclosed |
| WO-1998004917-A1 | BORON NEUTRON CAPTURE THERAPY USING PRE-TARGETING METHODS | IMMUNOMEDICS INC. (US) | 1998-02-05 | — | — | WO | disclosed |
| US-5569446-A | Radiohalogenation of proteins using trihalophenyl derivatives | BRACCO INTERNATIONAL B.V. | 1996-10-29 | — | — | US | disclosed |
| US-5463080-A | 2,4,6-triiodo-1,3-benzenedicarboxylic acid compounds used as radiolabelling reagents | BRACCO INTERNATIONAL B.V. (NL) | 1995-10-31 | — | — | US | disclosed |
| US-5290937-A | Radiolabeling of proteins using alkoxyphenol derivatives | E. R. SQUIBB & SONS, INC. (US) | 1994-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327443-A1 | TRITERPENE SAPONIN ANALOGUES | LSS, NFATC1, PGGT1B | PTPN2 457/4885PTPN1 689/4885TPMT 3368/4885 |
| US-12569554-B2 | Triterpene saponin analogues | TLR4, TLR7, TLR8 | PTPN2 383/4885PTPN1 522/4885TPMT 2898/4885 |
| US-20260115281-A1 | TRITERPENE SAPONIN ANALOGUES | NR1H2, NR1H3, LSS | PTPN2 469/4885PTPN1 337/4885TPMT 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.